Clinical Trial Update: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial comparing three versus five years of adjuvant imatinib in patients with operable gastrointestinal stromal tumor (GIST).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Sarcoma

Drugs mentioned

• Imatinib (Gleevec) (imatinib)

Snippet

Sponsor: Heikki Joensuu | Conditions: Sarcoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING